Results:
Between November 2021 and March 2022, a total of 62 subjects received Sotrovimab infusion at AUBMC. Patients had a mean age of 59.7 years and an average Body Mass Index (BMI) of 26.72 Kg/m2. Most of the patients were males (66.1%), and almost half were smokers (51.6%).
More than 70% of subjects were vaccinated against COVID-19 (Pfizer AstraZeneca, Sinopharm, and other various vaccines), and 25 (43.1%) out of 62 had received two doses of any COVID-19 vaccine. The average duration of symptoms before hospital presentation was 3.97±4.5 days. The baseline characteristics are shown in Table 1.
Regarding patient comorbidities, hypertension was the most common and was present in 56.5% of subjects, followed by hematological malignancies with a rate of 35.5%. The prevalence rates of all comorbidities are listed in (Figure1) ,
The subject population was grouped according to the NIH criteria for prioritizing the use of anti-SARS-CoV-2 therapies [15] and it was found that 77% of the population belonged to Tier 1, 8.1 % to Tier 2, and 14.5 % to Tier 3 (Table 2) .
Concerning the ongoing chronic treatment of the subjects, 40.3% of the 62 subjects were on active chemotherapy and 17.7% of them were currently receiving or previously received rituximab within the past 12 months (Table 3) .
We calculated the primary and the secondary outcomes using SPSS by adding the patients with the specific outcome to generate the total number (N) and we divided them by the total number of patients to get the percentage (%). For the primary outcomes, 39 subjects received the drug in the ED and did not require hospitalization (62.9%). 23 subjects (37.1%) were hospitalized: 13 of them required hospitalization due to COVID- 19 (and received Sotrovimab subsequently), whereas the other 10 patients were already hospitalized when they acquired COVID-19 infection. Thirteen patients (21.0%) experienced clinical deterioration 24 hours after Sotrovimab infusion and only four patients (6.5%) died due to any cause at 60 days after the infusion. For the secondary outcomes, six patients (9.7%) out of the total subjects progressed to critical illness and no adverse events were reported in any of the subjects (Table-4).
Concerning the appropriateness of Sotrovimab use based on the institution criteria developed as mentioned above, we found that Sotrovimab administration was appropriate and in compliance with the NIH-derived institution criteria in 61 out of the 62 (98.4%) patients.